Unveiling reversibility and plasticity in cardiac hypertrophy: insights from a transverse aortic constriction-release model

Manabu Shiraishi
DOI: https://doi.org/10.1101/2024.07.07.602358
2024-08-02
Abstract:Transverse aortic constriction (TAC) is a well-established animal model used to study the pathomechanisms of pressure overload-induced heart failure. A number of studies have shown that treatment of the heart failure in this model may reverse the associated hypertrophy and fibrosis. However, because no TAC-release model in which hemodynamics improve upon alleviation of the physical stenosis has yet been established, the histologic changes and regulatory molecular biological mechanisms underlying the reversibility of cardiac hypertrophy and fibrosis are unknown. This study was conducted to establish an animal TAC-release model and thereby investigate the mechanisms that govern reversibility and plasticity of myocardial hypertrophy, fibrosis, and angiogenesis. TAC surgery was performed on rats, and 4 weeks later TAC release was achieved by cutting the constricting threads. TAC-subjected heart exhibited severe myocardial hypertrophy, fibrosis, and increased angiogenesis, along with diastolic dysfunction. Heart released from TAC showed reduced hypertrophy and fibrosis and improved diastolic function. Gene expression analysis uncovered regulator of calcineurin 1 (Rcan1) as a key player in cardiac function and histologic changes after TAC release. Rcan1 knockdown exacerbated myocardial hypertrophy and fibrosis in heart released from TAC. The left ventricular afterload relief model revealed that increased oxidative stress and Rcan1 upregulation, which suppresses the calcineurin-NFAT pathway, are key to structural and functional recovery from pressure overload-induced cardiac hypertrophy.
Molecular Biology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to study the reversibility and plasticity mechanisms of these pathological changes in cardiac hypertrophy and fibrosis by establishing a transverse aortic constriction - release (TAC - release) model. Specifically, researchers hope to understand whether cardiomyocyte hypertrophy, fibrosis, and angiogenesis can be reversed after relieving the physical stenosis that causes cardiac pressure overload, as well as the molecular biological mechanisms involved in this process. The study particularly focuses on the role of Regulator of Calcineurin 1 (Rcan1) in cardiac function recovery and histological changes. The main findings of the paper include: 1. **Model establishment and validation**: By performing TAC surgery in rats and releasing the constriction 4 weeks later, the TAC - release model was successfully established. This model shows the structural and functional changes of the heart after pressure overload and the reversal of these changes after relieving the overload. 2. **Histological and functional changes**: TAC - treated hearts showed severe myocardial hypertrophy, fibrosis, and angiogenesis, accompanied by diastolic dysfunction. After TAC release, heart hypertrophy and fibrosis were alleviated, and diastolic function was improved. 3. **Gene expression analysis**: Gene expression analysis revealed the crucial role of Rcan1 in cardiac function and histological changes. Knockdown of Rcan1 exacerbated myocardial hypertrophy and fibrosis. 4. **Role of oxidative stress**: The study found that after TAC release, due to the reduction of left ventricular afterload, coronary reperfusion increased, resulting in an elevated level of oxidative stress. The up - regulation of Rcan1 may help the heart recover from pressure - overload - induced hypertrophy by inhibiting the calcineurin - NFAT signaling pathway. In conclusion, through the TAC - release model, this study thoroughly explored the reversibility and plasticity mechanisms of cardiac hypertrophy and fibrosis, especially the important role of Rcan1 in this process. These findings provide new insights for the development of treatment strategies for heart failure.